Page last updated: 2024-08-24

topotecan and Glioma

topotecan has been researched along with Glioma in 39 studies

Research

Studies (39)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	11 (28.21)	18.2507
2000's	18 (46.15)	29.6817
2010's	9 (23.08)	24.3611
2020's	1 (2.56)	2.80

Authors

Authors	Studies
Agar, NYR; Al-Dalahmah, O; Argenziano, MG; Banu, MA; Behl, M; Boyett, DM; Bruce, JN; Canoll, P; Catania, V; D'Amico, RS; Furnari, JL; Gill, BJA; Good, L; Grinband, J; Higgins, DMO; Humala, N; Iwamoto, FM; Jambawalikar, S; Lassman, AB; Lignelli, A; Mahajan, A; Marie, T; Mintz, A; Neira, JA; Pereira, B; Petridis, P; Regan, MS; Save, AV; Sims, PA; Spinazzi, EF; Stopka, SA; Sudhakar, TD; Upadhyayula, PS; Welch, MR; Wu, PB; Zacharoulis, S; Zhao, W	1
Li, Z; Liu, LB; Liu, XB; Liu, YH; Wang, P; Xue, YX; Zhang, FL	1
Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D	1
Bruce, JN; DeLaPaz, R; Kennedy, BC; Surapaneni, K; Yanagihara, TK	1
Babich, JW; Boyd, M; Gaze, MN; Mairs, RJ; McCluskey, AG; Pimlott, SL	1
Anver, MR; Bonomi, CA; Borgel, SD; Carter, JP; Gehrs, B; Hollingshead, M; Kinders, RJ; Melillo, G; Parchment, R; Raffeld, M; Rapisarda, A; Shoemaker, RH; Uranchimeg, B	1
Calabrese, C; Carcaboso, AM; Elmeliegy, MA; Juel, SJ; Shen, J; Stewart, CF; Tracey, L; Waters, CM; Zhang, ZM	1
Kivivuori, SM; Lönnqvist, T; Riikonen, P; Saarinen-Pihkala, UM; Valanne, L	1
Allen, JC; Belasco, JB; Fisher, PG; Janss, AJ; Minturn, JE; Patti, R; Phillips, PC	1
Bagiella, E; Bruce, JN; Canoll, P; DeLaPaz, RL; Fine, RL; Kennedy, BC; Lai, R; Rosenfeld, SS; Sands, SA; Surapaneni, K; Yanes, CL; Yun, J	1
Arias-Mendoza, F; Bagiella, E; Brown, T; Bruce, JN; Bruce, SS; Canoll, P; Dashnaw, S; Mohajed, H; Romanov, A; Sebastian, M; Sonabend, AM; Stuart, RM; Yanagihara, T; Yun, J	1
Anderson, RC; Bruce, JN; Canoll, P; Feldstein, NA; Garvin, J; Kennedy, B; Needle, M; Yanes, CL	1
Melillo, G; Rapisarda, A; Sausville, EA; Scudiero, DA; Selby, M; Shoemaker, RH; Uranchimeg, B	1
Ater, J; Geyer, JR; Krailo, MD; Mehta, MP; Needle, MN; Sanghavi, SN	1
Albani, M; Bucsky, P; Emser, A; Erdlenbruch, B; Gnekow, A; Kühl, J; Längler, A; Peters, O; Völpel, S; Wagner, S; Wolff, JE	1
Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Salmaggi, A	1
Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Fariselli, L; Fumagalli, L; Gelati, M; Salmaggi, A; Sciacca, F	1
Bernier-Chastagner, V; Bracard, S; Chastagner, P; Doz, F; Gentet, JC; Grill, J; Kalifa, C; Laithier, V; Lejars, O; Luporsi, E; Margueritte, G; Marie-Cardine, A; Mechinaud, F; Millot, F	1
Angerson, WJ; Boyd, M; Clark, AM; Cosimo, E; Gaze, MN; Mairs, RJ; McCluskey, AG; Ross, SC	1
Barberi-Heyob, M; Chastagner, P; Marchal, C; Merlin, JL; Pinel, S; Taghian, A	1
Blaney, SM; Burger, P; Chintagumpala, MM; Friedman, HS; Holmes, E; Horowitz, ME; Kepner, J; Kun, LE; McCluggage, C; McLendon, RE; Michalski, J; Modrich, PL; Rutka, J; Stewart, CF; Thompson, S; Woo, S	1
Bankiewicz, KS; Berger, MS; Drummond, DC; Kirpotin, DB; Krauze, MT; Noble, CO; Park, JW; Saito, R	1
Weller, M	1
Bjornsti, MA; Chang, CF; Gordon, J; Kerr, DA; Khalili, K	1
Adamson, PC; Allen, JC; Balis, FM; Berg, SL; Blaney, SM; Heideman, RL; Horowitz, ME; Jakacki, RI; Lange, BJ; Packer, RJ; Phillips, PC; Poplack, DG; Reaman, GH; Sallan, SE	1
Boothman, DA; Lamond, JP; Mehta, MP	1
Fueyo, J; Gomez-Manzano, C; Kyritsis, AP; Levin, VA; Martin-Duque, P; Perez-Soler, R; Puduvalli, VK; Yung, WK	1
Weller, M; Winter, S	1
Barone, TA; Ciesielski, MJ; Fenstermaker, RA; Greenberg, SJ; Lis, A; Plunkett, RJ; Pollina, J	1
Arbuck, S; Cokgor, I; Fields, S; Friedman, AH; Friedman, HS; Graden, D; Houghton, PJ; Kerby, T; McLendon, RE; Zilisch, JE	1
Dooley, NP; Gladson, CL; Kyritsis, AP; Rao, JS; Uhm, JH	1
Loos, WJ; Schellens, JH; Straathof, CS; van den Bent, MJ; Vecht, CJ	1
Bom, D; Burke, TG; Curran, DP; Erff, M; Pollack, IF; Strode, JT	1
Bartussek, C; Naumann, U; Weller, M	1
Bernath, AM; Buckner, JC; Burch, PA; Cascino, TL; Kugler, JW; Nair, S; Novotny, P; Pfeifle, DM; Scheithauer, BW; Tschetter, LK	1
Bruce, JN; Chakrabarti, I; Chi, JH; Hall, JS; Hurley, PT; Kaiser, MG; Parsa, AT	1
Gooley, T; Hawkins, D; Lindsley, K; Matthay, KK; Park, JR; Sanders, JE; Slattery, J; Villablanca, JG	1
Bruce, JN; Chakrabarti, I; Fine, RL; Hall, JS; Kaiser, MG; Parsa, AT	1
Naumann, U; Rieger, J; Schmidt, F; Weller, M; Wischhusen, J	1

Trials

10 trial(s) available for topotecan and Glioma

Article	Year
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. The Lancet. Oncology, 2022, Volume: 23, Issue:11 Topics: Convection; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Topotecan	2022
A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatric blood & cancer, 2011, Volume: 56, Issue:1 Topics: Brain Neoplasms; Brain Stem Neoplasms; Child; Disease-Free Survival; Ependymoma; Female; Glioma; Humans; Male; Neuroectodermal Tumors, Primitive; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2011
A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952. Neuro-oncology, 2003, Volume: 5, Issue:1 Topics: Adolescent; Brain Stem Neoplasms; Child; Child, Preschool; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Radiation-Sensitizing Agents; Survival Rate; Topotecan	2003
Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer, 2004, Apr-15, Volume: 100, Issue:8 Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Glioma; Humans; Male; Topotecan; Treatment Outcome	2004
Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study. Cancer, 2005, Dec-15, Volume: 104, Issue:12 Topics: Adolescent; Age Factors; Brain Stem Neoplasms; Child; Child, Preschool; Disease-Free Survival; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Risk Assessment; Survival Analysis; Time Factors; Topotecan; Treatment Outcome	2005
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. Journal of neuro-oncology, 2006, Volume: 77, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carrier Proteins; Child; Child, Preschool; Disease-Free Survival; Female; Glioma; Humans; Immunohistochemistry; Male; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm, Residual; Nuclear Proteins; Procarbazine; Survival Analysis; Topotecan	2006
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer, 1996, Aug-01, Volume: 78, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Infant; Infusions, Intravenous; Male; Topotecan	1996
Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer, 1999, Mar-01, Volume: 85, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Topotecan; Treatment Outcome	1999
A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Investigational new drugs, 2000, Volume: 18, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Topotecan	2000
Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Medical and pediatric oncology, 2000, Volume: 35, Issue:6 Topics: Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Glioma; Hematopoietic Stem Cell Transplantation; Humans; Infant; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan	2000

Other Studies

29 other study(ies) available for topotecan and Glioma

Article	Year
Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells. PloS one, 2013, Volume: 8, Issue:11 Topics: Apoptosis; Brain Neoplasms; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Glioma; Humans; Naphthoquinones; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Topotecan	2013
Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. Pediatric blood & cancer, 2014, Volume: 61, Issue:9 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Case-Control Studies; Celecoxib; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Child, Preschool; Etoposide; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Grading; Prognosis; Pyrazoles; Quality of Life; Remission Induction; Sulfonamides; Survival Rate; Thalidomide; Topotecan	2014
Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma. World neurosurgery, 2015, Volume: 84, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Blood Volume; Brain Neoplasms; Cerebrovascular Circulation; Convection; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Predictive Value of Tests; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Burden	2015
Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination. The British journal of radiology, 2008, Volume: 81 Spec No 1 Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; Glioma; Mice; Mice, Nude; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Radiopharmaceuticals; Topotecan; Treatment Outcome	2008
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Molecular cancer therapeutics, 2009, Volume: 8, Issue:7 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Cell Proliferation; DNA Damage; Drug Synergism; Female; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Luciferases; Mice; Mice, Nude; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2009
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer research, 2010, Jun-01, Volume: 70, Issue:11 Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Topotecan; Xenograft Model Antitumor Assays	2010
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas. Acta paediatrica (Oslo, Norway : 1992), 2011, Volume: 100, Issue:1 Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Celecoxib; Child; Child, Preschool; Disease Progression; Etoposide; Glioma; Humans; Pilot Projects; Pyrazoles; Quality of Life; Radiation-Sensitizing Agents; Sulfonamides; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome	2011
Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery, 2011, Volume: 69, Issue:6 Topics: Adult; Aged; Attention; Convection; Drug Administration Schedule; Drug Delivery Systems; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Memory; Middle Aged; Neurologic Examination; Neuropsychological Tests; Prospective Studies; Quality of Life; Reaction Time; Supratentorial Neoplasms; Surveys and Questionnaires; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Topotecan; Young Adult	2011
Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro-oncology, 2011, Volume: 13, Issue:8 Topics: Animals; Brain Neoplasms; Contrast Media; Convection; Drug Delivery Systems; Gadolinium DTPA; Glioma; Humans; Image Processing, Computer-Assisted; Infusion Pumps, Implantable; Infusions, Subcutaneous; Liposomes; Magnetic Resonance Imaging; Male; Swine; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2011
Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. Journal of neurosurgery. Pediatrics, 2013, Volume: 11, Issue:3 Topics: Antineoplastic Agents; Biopsy; Brain; Brain Stem Neoplasms; Child, Preschool; Combined Modality Therapy; Convection; Drug Delivery Systems; Fatal Outcome; Female; Gait Disorders, Neurologic; Glioma; Humans; Image Processing, Computer-Assisted; Karnofsky Performance Status; Magnetic Resonance Imaging; Nervous System Diseases; Radiography; Topotecan; Treatment Outcome	2013
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer research, 2002, Aug-01, Volume: 62, Issue:15 Topics: Antineoplastic Agents; Camptothecin; DNA-Binding Proteins; DNA, Neoplasm; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Gene Expression; Glioma; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Luciferases; Lymphokines; Nuclear Proteins; Promoter Regions, Genetic; Response Elements; RNA, Messenger; Topotecan; Transcription Factors; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines. Oncology research, 2004, Volume: 14, Issue:7-8 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cisplatin; Dacarbazine; Doxorubicin; Drug Interactions; Glioma; Humans; Temozolomide; Topotecan; Tumor Cells, Cultured	2004
In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. Journal of neuro-oncology, 2005, Volume: 71, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Combined Modality Therapy; Glioma; Humans; Membrane Glycoproteins; Nervous System Neoplasms; Radiation, Ionizing; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Tumor Necrosis Factor-alpha	2005
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-01, Volume: 11, Issue:21 Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Comet Assay; DNA Damage; DNA Fragmentation; DNA, Complementary; Glioma; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Time Factors; Topotecan; Transfection	2005
Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts. Journal of neuro-oncology, 2006, Volume: 76, Issue:1 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Glioma; Humans; Mice; Mice, Nude; Topotecan; Transplantation, Heterologous	2006
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncology, 2006, Volume: 8, Issue:3 Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dose-Response Relationship, Drug; Drug Delivery Systems; Glioma; Humans; Liposomes; Male; Rats; Rats, Nude; Topotecan; Xenograft Model Antitumor Assays	2006
[Chemotherapy for brain tumors in adult patients]. Der Nervenarzt, 2008, Volume: 79, Issue:2 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Genetic Markers; Glioma; Humans; Lymphoma; Prognosis; Promoter Regions, Genetic; Temozolomide; Topotecan; Tumor Suppressor Proteins	2008
Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology, 1993, Volume: 196, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Chloramphenicol O-Acetyltransferase; DNA Replication; DNA Topoisomerases, Type I; Gene Expression Regulation, Viral; Glioma; Humans; JC Virus; Neuroglia; Promoter Regions, Genetic; Recombinant Fusion Proteins; Regulatory Sequences, Nucleic Acid; Topotecan; Transfection	1993
The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. Journal of neuro-oncology, 1996, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Central Nervous System Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Glioma; Humans; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1996
Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. International journal of oncology, 1998, Volume: 12, Issue:3 Topics: Adenoviridae; Antineoplastic Agents; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p16; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G1 Phase; Glioma; Humans; Paclitaxel; Recombinant Proteins; Time Factors; Topotecan; Transfection	1998
Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. The Journal of pharmacology and experimental therapeutics, 1998, Volume: 286, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Fas Ligand Protein; fas Receptor; Glioma; Humans; Membrane Glycoproteins; Mice; Proto-Oncogene Proteins c-bcl-2; RNA; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53	1998
Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model. Journal of neuro-oncology, 1998, Volume: 39, Issue:3 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Survival; Enzyme Inhibitors; Glioma; Humans; Infusions, Parenteral; Rats; Rats, Nude; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1998
Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:6 Topics: Antibodies, Monoclonal; Apoptosis; bcl-X Protein; Cell Survival; Fibronectins; Glioma; Humans; In Situ Nick-End Labeling; Integrins; Proto-Oncogene Proteins c-bcl-2; Receptors, Fibronectin; Receptors, Vitronectin; Topotecan; Tumor Cells, Cultured; Vitronectin	1999
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. Journal of neuro-oncology, 1999, Volume: 42, Issue:2 Topics: Animals; Brain; Brain Neoplasms; Dexamethasone; Female; Glioma; Rats; Rats, Inbred F344; Reference Values; Tissue Distribution; Topotecan	1999
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer research, 1999, Oct-01, Volume: 59, Issue:19 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; Genes, p53; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1999
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. Experimental cell research, 1999, Dec-15, Volume: 253, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carmustine; Cell Death; Cell Division; Cisplatin; Clone Cells; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Gene Expression Regulation, Neoplastic; Genes, Dominant; Glioma; Humans; In Vitro Techniques; Paclitaxel; Point Mutation; Radiotherapy; Teniposide; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vincristine	1999
Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery, 2000, Volume: 47, Issue:4 Topics: Animals; Antibody Formation; Antineoplastic Agents; Brain Neoplasms; Cell Division; Glioma; Immunity, Cellular; Immunotherapy; Male; Neoplasm Transplantation; Rats; Rats, Inbred F344; Rats, Wistar; Survival Analysis; Topotecan; Tumor Cells, Cultured	2000
Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery, 2000, Volume: 47, Issue:6 Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Glioma; Injections, Intraperitoneal; Neoplasm Transplantation; Rats; Rats, Wistar; Tissue Distribution; Topotecan; Tumor Cells, Cultured	2000
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. European journal of pharmacology, 2001, Jan-19, Volume: 412, Issue:1 Topics: Antineoplastic Agents; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; Genes, p53; Glioma; Humans; RNA, Messenger; Topotecan; Tumor Cells, Cultured	2001